CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination...

Read More